Source: Applied Clinical Trials

Teranga: SCOPE Summit 2025: Richard Young on CluePoints' Approach to Risk Detection in Clinical Trials

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, CEO, CluePoints, discusses goals of the SCOPE Summit and CluePoints' evolving approach to risk detection.

Read full article »
Teranga's Competitors | Teranga's News | Teranga's Financials
Stay up-to-date with the latest news on Teranga
Est. Annual Revenue
$500M-1.0B
Est. Employees
1.0-5.0K
Richard Young's photo - President & CEO of Teranga

President & CEO

Richard Young

CEO Approval Rating

70/100

Read more
Stay up-to-date with the latest news on Teranga